Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Egypt / NCT07498998
Starting soon Not applicable

Glucocorticoid, Ozone and 5% Dextrose Local Injection for Pain Relief in Carpal Tunnel Syndrome

NCT07498998 · tracked via the Priya Life Science Egypt tracker
Phase
Not applicable
Started
2026-07-30
Last updated
2026-03-27

Condition(s) studied

Carpal Tunnel Syndrome (CTS)GlucocorticoidPainDextrose

Investigational drug(s) / intervention(s)

Perineural injection with 5% dextrose (D5W).Local ozone injectionLocal glucocorticoid injection (dexamethasone).

Perineural injection with 5% dextrose (D5W).: Group 1: Perineural injection with 5% dextrose (D5W).

Local ozone injection: Group 2: Local ozone injection

Local glucocorticoid injection (dexamethasone).: Group 3: Local glucocorticoid injection (dexamethasone).

Study summary

This study aims to compare the efficacy and outcomes of perineural injection with 5% dextrose, local ozone and glucocorticoid injection in the management of carpal tunnel syndrome.

Eligibility

Sex
ALL
Min age
18 Years
Max age
65 Years
Healthy volunteers
No
Inclusion Criteria: * Adults aged 18-65 years with a clinical diagnosis of mild to moderate Carpal Tunnel Syndrome . * Clinical diagnosis of mild to moderate Carpal Tunnel Syndrome , as classified by Bland neurophysiological classification scale: Mild Carpal Tunnel Syndrome : Slow Distal Sensory Latency(≥3.6 ms), Normal Distal Motor Latency(\< 4.5 ms) * Moderate Carpal Tunnel Syndrome : Slow Distal Sensory Latency (≥ 3.6 ms), Slow Distal Motor Latency (4.5 - 6.4 ms) * Failure to respond to conservative treatments (e.g., splinting, activity modification, or oral medications) for at least 6 weeks. Exclusion Criteria: * Patient refusal. * Severe Carpal Tunnel Syndrome requiring surgical intervention, as defined by the Bland neurophysiological classification scale: Severe Carpal Tunnel Syndrome: Absent Distal Sensory Latency and Slow Distal Motor Latency (4.5 - 6.4 ms) * Previous corticosteroid injection for Carpal Tunnel Syndrome within the last 6 months. * History of wrist trauma, surgery or anatomical abnormalities. * Systemic conditions such as diabetes mellitus, thyroid dysfunction or rheumatoid arthritis. * Pregnancy or lactation. * Contraindications to any of the study interventions (e.g., allergy to glucocorticoids or ozone). * Infection at wrist.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Tanta University Tanta Egypt

More Tanta University trials in Egypt

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07498998 on ClinicalTrials.gov ↗ ← All trials in Egypt